Glaukos Announces Retirement of William J. Link, PhD, as Chairman of the Board; and Appointment of Thomas W. Burns as New Chairman

Glaukos Announces Retirement of William J. Link, PhD, as Chairman of the Board; and Appointment of Thomas W. Burns as New Chairman

December 22, 2021

Glaukos announced that William J. Link, PhD, will step down as Chairman of the Board of Directors on December 31, 2021. Since June 2001, Dr. Link has served as Chairman of the Glaukos Board of Directors.

Following Dr. Link's retirement, the Board has appointed Thomas W. Burns, Glaukos' President and Chief Executive Officer and a director on the Board since 2002, to serve as Chairman of the Board, starting December 31, 2021. Mr. Burns will remain as President and CEO of the company.

Mark J. Foley, who has been on the Board since 2014 and is the chair of the Compensation, Nominating, and Governance Committee, has also been named as the Board's lead independent director by the independent members.

"We're grateful for Bill’s leadership and contributions over the past 20 years, helping to guide Glaukos’ transformational evolution from an early-stage startup into a global, diversified, ophthalmic drug and device leader," said Mark J. Foley, lead independent director and chair of the Compensation, Nominating and Governance Committee.

"It's been my privilege to serve Glaukos and its many stakeholders, and I am grateful to the Board and my colleagues, both past and present, for their support during my tenure," said Dr. Link.

“Glaukos will be in great hands with Tom’s continued leadership and is well-positioned to drive meaningful innovation to address unmet needs in large and underserved patient populations suffering from chronic eye diseases,” he added.

“On behalf of the entire Glaukos organization, I am deeply grateful to Bill for his unwavering commitment and decades of dedicated leadership and service to Glaukos. His guidance, vision and expertise have been instrumental to Glaukos’ growth and development," said Mr. Burns. "It's my honor to continue working alongside the Board and our global teams as we continue to advance our mission to transform the treatment of chronic eye diseases for the benefit of patients worldwide."